AI researchers, computational scientists, and engineers publishing at NeurIPS 2026 (29 papers across 10 workshops), AAAI, Stanford, and ELLIS — across drug discovery, financial AI, and materials science. Our key application is Alzheimer's reversal, within the broader area of drug design and biological discovery.
Nearly 5 decades of experience at the forefront of technology and innovation. AI researcher since the 1990s. Former EVP at META, with senior leadership roles at Microsoft, Samsung, and Oracle. Educational background and academic affiliations include Harvard, Stanford, and Caltech. Author of 100+ accepted peer-reviewed papers spanning AI, computational biology, and multi-agent systems, including 22+ bio-focused papers. Delivered an AAAI-26 oral presentation and serves as an IROS invited speaker. Founding member of the Caltech-MIT Enterprise Forum. Creator of the Validated Accelerated Pipeline (VAP) and Automated Computational Hypothesis Testing (ACHT) frameworks that form the backbone of our platform.
Co-author of 80+ accepted peer-reviewed papers in computational biology, AI drug discovery, and multi-agent systems, including 28+ bio-focused papers. Deep expertise in multi-agent system architecture and the principal architect of the AI-Scientist v2 framework. Community Fund Board Member of Energy Web Foundation (alongside Deloitte, Shell, EF), bringing a decade of experience in scaling technology ventures from concept to production. Bridges the gap between cutting-edge research and practical deployment, ensuring our computational tools deliver real-world results.
Our research team brings diverse expertise in computational chemistry, machine learning, structural biology, and quantitative finance.
We are looking for exceptional researchers and engineers. If you publish at top-tier venues and want to work on drug discovery, financial AI, or materials science, we want to hear from you.